GPC2 expression is observed in nearly 90% of MYCN amplified NB cell lines (Figure 4B), together with the potent efficacy of CT3 CAR T cells in regressing xenograft tumors (IMR5 and NBEB) with MYCN amplification; therefore, we identify GPC2 as a potential immunotherapeutic target against MYCN-amplified NB. This evidence concerns the gene CAGE1 and neuroblastoma.